Ramagopal Tumuluri, MD
Interventional Cardiology · Brookfield, WINPI 1063489615
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,329 of the $9,086 with a category attached, or 69.7%. 51 manufacturers reported payments, led by Medtronic at 39.8% of the total. Reporting peaked in 2024 at $5,418 and has fallen 71.1% since, to $1,564 in 2025.
Across 192 payments — averaging $47.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Inari Medical, Inc.$610
- Abbott$506
- Boston Scientific$372
- Novartis$279
- United Therapeutics Corporation$264
- plus $3K from 45 others
Across 109 payments — averaging $1257.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$134K
- Angiodynamics, Inc.$2K
- Actelion Pharmaceuticals, Ltd$450
What the payments were for
- Travel & lodging$2,72130%
- Food & beverage$6,32970%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELLIPSYS VASCULAR ACCESS SYSTEM$1,057
- VenaSeal$835
- TurboHawk$705
- FLOWTRIEVER CATHETER, S$610
- CT THROMBECTOMY SYSTEM KIT$610
- Perclose ProStyle$211
- ONYX FRONTIER$171
- TYVASO$148
- ORENITRAM$148
- REMODULIN$148
- GRAFIX PL$148
- Oasis$148
- Stravix$148
- VENOVO$143
- UPTRAVI$125
- OPSUMIT$125
- Indigo System$119
- JOT DX$112
How this compares
$9,086 in reported general payments places this provider in the 65th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 17 | $216,774 |
| EliquisApixaban | 149 | $130,793 |
| EntrestoSacubitril/Valsartan | 84 | $78,547 |
| JardianceEmpagliflozin | 46 | $44,597 |
| XareltoRivaroxaban | 30 | $32,814 |
| FarxigaDapagliflozin Propanediol | 20 | $17,343 |
| Repatha SureclickEvolocumab | 15 | $11,526 |
| ClopidogrelClopidogrel Bisulfate | 142 | $2,005 |
| Metoprolol Succinate | 154 | $1,807 |
| Bumetanide | 64 | $1,564 |
| Atorvastatin Calcium | 134 | $1,463 |
| Potassium Chloride | 109 | $1,333 |
| Niacin ErNiacin | 12 | $1,280 |
| Flecainide Acetate | 26 | $1,266 |
| Cilostazol | 47 | $1,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $169 | $216,77417 claims |
| PfizerEliquis | $69 | $130,793149 claims |
| NovartisEntresto | $279 | $78,54784 claims |
| Boehringer IngelheimJardiance | $35 | $44,59746 claims |
| Johnson & JohnsonXarelto | $18 | $32,81430 claims |
| AstraZenecaFarxiga | $220 | $17,34320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Brookfield
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Raaid MuseitifKenosha$71K
- Iyad AzzamMilwaukee$60K
- Mark HoffmannWausau$52K
- Montoya TaylorMilwaukee$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.